[Clinical development of a drug for brain aging. Current limitations and future prospects].
The clinical development of any drug used in the treatment of brain-ageing, poses many methodological problems regarding the difficulty in defining precisely the pathology, both from the point of view of diagnostic and of terminology, the lack of specific parameters for assessing the therapeutic efficacy and the difficulty of establishing homogeneous trial sample, since the geriatric population is a very heterogeneous whole. The authors, in the light of the research done, state their methodology and give their directives; among them: common training for all the examiners, in order to make execution and classification of the tests extremely homogeneous the drug is evaluated through psychometric tests, which analyze the patient both physically and mentally.
Zerbini
O
O
Recchia
G
G
Fabbri
L
L
D000108:Acetylcarnitine / Q000627:therapeutic use*; D000368:Aged; D002331:Carnitine / Q000031:analogs & derivatives*; D002986:Clinical Trials as Topic; D003704:Dementia / Q000175:diagnosis / Q000188:drug therapy*; D003937:Diagnosis, Differential; D006801:Humans; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D019965:Neurocognitive Disorders / Q000175:diagnosis / Q000188:drug therapy*; D012106:Research
D000108:Acetylcarnitine; D002331:Carnitine
Sviluppo clinico di un farmaco per l'invecchiamento cerebrale. Limiti attuali e prospettive future.